{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:01:21Z","timestamp":1790776881369,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["HNO"],"DOI":"10.1007\/s00106-026-01812-7","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:36:34Z","timestamp":1790775394000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Spezielle Tumorentit\u00e4ten","Special tumor entities"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9290-8427","authenticated-orcid":false,"given":"Rubens","family":"Th\u00f6lken","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J.","family":"Schuler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Zenk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Doescher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"1812_CR1","doi-asserted-by":"publisher","first-page":"6009","DOI":"10.1200\/JCO.2026.44.16_suppl.6009","volume":"44","author":"R Ferrarotto","year":"2026","unstructured":"Ferrarotto\u00a0R, Swiecicki\u00a0P, Ho\u00a0AL et\u00a0al (2026) Clinical activity of REM-422, a MYB mRNA degrader, in recurrent\/metastatic adenoid cystic carcinoma. JCO 44:6009\u20136009","journal-title":"JCO"},{"key":"1812_CR2","doi-asserted-by":"publisher","first-page":"6119","DOI":"10.1200\/JCO.2026.44.16_suppl.6119","volume":"44","author":"D McGrail","year":"2026","unstructured":"McGrail\u00a0D, Lazar Neto\u00a0F, Mitani\u00a0Y et\u00a0al (2026) AL101 in NOTCH1-activated adenoid cystic carcinoma: Biological effects and biomarker correlates. JCO 44:6119\u20136119","journal-title":"JCO"},{"key":"1812_CR3","doi-asserted-by":"publisher","first-page":"6010","DOI":"10.1200\/JCO.2026.44.16_suppl.6010","volume":"44","author":"GJ Hanna","year":"2026","unstructured":"Hanna\u00a0GJ, Rabinowits\u00a0G, Attarian\u00a0S et\u00a0al (2026) Emiltatug ledadotin, a B7-H4-directed antibody-drug conjugate, in aggressive adenoid cystic carcinoma. JCO 44:6010\u20136010","journal-title":"JCO"},{"key":"1812_CR4","doi-asserted-by":"publisher","first-page":"6122","DOI":"10.1200\/JCO.2026.44.16_suppl.6122","volume":"44","author":"DH Kim","year":"2026","unstructured":"Kim\u00a0DH, Hwang\u00a0W, Lee\u00a0S et\u00a0al (2026) Artificial intelligence-powered spatial analysis to predict response to axitinib in adenoid cystic carcinoma. JCO 44:6122\u20136122","journal-title":"JCO"},{"key":"1812_CR5","doi-asserted-by":"publisher","first-page":"6011","DOI":"10.1200\/JCO.2026.44.16_suppl.6011","volume":"44","author":"I Kinoshita","year":"2026","unstructured":"Kinoshita\u00a0I, Kano\u00a0S, Honma\u00a0Y et\u00a0al (2026) Trastuzumab deruxtecan in HER2-low recurrent\/metastatic salivary gland carcinoma: MYTHOS. JCO 44:6011\u20136011","journal-title":"JCO"},{"key":"1812_CR6","doi-asserted-by":"publisher","first-page":"6012","DOI":"10.1200\/JCO.2026.44.16_suppl.6012","volume":"44","author":"AL Ho","year":"2026","unstructured":"Ho\u00a0AL, Kaur\u00a0V, Patel\u00a0SA et\u00a0al (2026) Darolutamide plus leuprolide acetate in androgen receptor-positive salivary gland cancer. JCO 44:6012\u20136012","journal-title":"JCO"},{"key":"1812_CR7","doi-asserted-by":"publisher","first-page":"6028","DOI":"10.1200\/JCO.2026.44.16_suppl.6028","volume":"44","author":"V Subbiah","year":"2026","unstructured":"Subbiah\u00a0V et\u00a0al (2026) Efficacy and safety of pralsetinib in advanced or metastatic RET-altered thyroid cancer: Final analysis of the phase 1\/2 ARROW study. JCO 44:6028\u20136028","journal-title":"JCO"},{"key":"1812_CR8","doi-asserted-by":"publisher","first-page":"6021","DOI":"10.1200\/JCO.2026.44.16_suppl.6021","volume":"44","author":"M Tahara","year":"2026","unstructured":"Tahara\u00a0M et\u00a0al (2026) Nivolumab plus lenvatinib for unresectable anaplastic thyroid cancer: NAVIGATION. JCO 44:6021\u20136021","journal-title":"JCO"},{"key":"1812_CR9","doi-asserted-by":"publisher","first-page":"6117","DOI":"10.1200\/JCO.2026.44.16_suppl.6117","volume":"44","author":"A Lawless","year":"2026","unstructured":"Lawless\u00a0A, Fournier\u00a0I, Cabanillas\u00a0ME et\u00a0al (2026) Palliative neck radiation therapy with lenvatinib\/pembrolizumab in BRAF wild-type anaplastic thyroid cancer. JCO 44:6117\u20136117","journal-title":"JCO"},{"key":"1812_CR10","doi-asserted-by":"publisher","first-page":"6041","DOI":"10.1200\/JCO.2026.44.16_suppl.6041","volume":"44","author":"H Chen","year":"2026","unstructured":"Chen\u00a0H, Fu\u00a0H, Guo\u00a0W et\u00a0al (2026) First-in-class Trop2-targeted PET imaging with 68Ga-MY6349 for recurrent\/metastatic thyroid cancer. JCO 44:6041\u20136041","journal-title":"JCO"},{"key":"1812_CR11","doi-asserted-by":"publisher","first-page":"6033","DOI":"10.1200\/JCO.2026.44.16_suppl.6033","volume":"44","author":"S He","year":"2026","unstructured":"He\u00a0S, Huang\u00a0Y, Liu\u00a0GY et\u00a0al (2026) Cadonilimab plus chemotherapy versus chemotherapy alone in immunotherapy-refractory recurrent or metastatic nasopharyngeal carcinoma: CONQUEST. JCO 44:6033\u20136033","journal-title":"JCO"},{"key":"1812_CR12","doi-asserted-by":"publisher","first-page":"6036","DOI":"10.1200\/JCO.2026.44.16_suppl.6036","volume":"44","author":"J Ma","year":"2026","unstructured":"Ma\u00a0J, Xu\u00a0C, Qu\u00a0S et\u00a0al (2026) Penpulimab plus anlotinib and capecitabine as first-line treatment for recurrent\/metastatic nasopharyngeal carcinoma. JCO 44:6036\u20136036","journal-title":"JCO"},{"key":"1812_CR13","doi-asserted-by":"publisher","first-page":"6060","DOI":"10.1200\/JCO.2026.44.16_suppl.6060","volume":"44","author":"J Ma","year":"2026","unstructured":"Ma\u00a0J, Liang\u00a0YL, Xia\u00a0Y et\u00a0al (2026) HLX43 in previously treated recurrent\/metastatic nasopharyngeal carcinoma. JCO 44:6060\u20136060","journal-title":"JCO"},{"key":"1812_CR14","doi-asserted-by":"publisher","first-page":"TPS6130","DOI":"10.1200\/JCO.2026.44.16_suppl.TPS6130","volume":"44","author":"L Liu","year":"2026","unstructured":"Liu\u00a0L et\u00a0al (2026) Becotatug vedotin plus pucotenlimab as first-line therapy in recurrent or metastatic nasopharyngeal carcinoma. JCO 44:TPS6130\u2013TPS6130","journal-title":"JCO"},{"key":"1812_CR15","doi-asserted-by":"publisher","first-page":"6078","DOI":"10.1200\/JCO.2026.44.16_suppl.6078","volume":"44","author":"C Zhang","year":"2026","unstructured":"Zhang\u00a0C, Kuang\u00a0YW, Lu\u00a0J et\u00a0al (2026) Prognostic value and role of imaging extranodal extension in nasopharyngeal carcinoma. JCO 44:6078\u20136078","journal-title":"JCO"},{"key":"1812_CR16","doi-asserted-by":"publisher","first-page":"9506","DOI":"10.1200\/JCO.2026.44.16_suppl.9506","volume":"44","author":"CA Barker","year":"2026","unstructured":"Barker\u00a0CA, Wuthrick\u00a0EJ, Lanning\u00a0RM et\u00a0al (2026) Response-adapted definitive radiotherapy and cemiplimab-rwlc immunotherapy for locally advanced, unresectable cutaneous squamous cell carcinoma: RAMPART. JCO 44:9506\u20139506","journal-title":"JCO"},{"key":"1812_CR17","doi-asserted-by":"publisher","first-page":"6083","DOI":"10.1200\/JCO.2026.44.16_suppl.6083","volume":"44","author":"D Rischin","year":"2026","unstructured":"Rischin\u00a0D, Porceddu\u00a0SV, Day\u00a0F et\u00a0al (2026) C\u2011POST study of adjuvant cemiplimab for high-risk cutaneous squamous cell carcinoma: Disease-free survival analyses. JCO 44:6083\u20136083","journal-title":"JCO"},{"key":"1812_CR18","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1056\/NEJMoa2502449","volume":"393","author":"D Rischin","year":"2025","unstructured":"Rischin\u00a0D, Porceddu\u00a0SV, Day\u00a0F et\u00a0al (2025) Adjuvant cemiplimab or placebo in high-risk cutaneous squamous-cell carcinoma. N Engl J Med 393:645\u2013656","journal-title":"N Engl J Med"},{"key":"1812_CR19","doi-asserted-by":"publisher","first-page":"9585","DOI":"10.1200\/JCO.2026.44.16_suppl.9585","volume":"44","author":"E Mu\u00f1oz Couselo","year":"2026","unstructured":"Mu\u00f1oz Couselo\u00a0E, Montaudie\u00a0H, Ruiz\u00a0ES et\u00a0al (2026) Cosibelimab for locally advanced cutaneous squamous cell carcinoma: Updated follow-up. JCO 44:9585\u20139585","journal-title":"JCO"},{"key":"1812_CR20","doi-asserted-by":"publisher","first-page":"9586","DOI":"10.1200\/JCO.2026.44.16_suppl.9586","volume":"44","author":"S Inoue","year":"2026","unstructured":"Inoue\u00a0S, Maruyama\u00a0A, Yamamoto\u00a0Y et\u00a0al (2026) Oral S\u20111 for locally advanced or recurrent\/metastatic cutaneous squamous cell carcinoma. JCO 44:9586\u20139586","journal-title":"JCO"}],"container-title":["HNO"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00106-026-01812-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00106-026-01812-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00106-026-01812-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:36:35Z","timestamp":1790775395000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00106-026-01812-7"}},"subtitle":["Neuigkeiten von der ASCO-Jahresversammlung 2026","New results at the 2026 ASCO Annual Meeting"],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":20,"alternative-id":["1812"],"URL":"https:\/\/doi.org\/10.1007\/s00106-026-01812-7","relation":{},"ISSN":["0017-6192","1433-0458"],"issn-type":[{"value":"0017-6192","type":"print"},{"value":"1433-0458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"assertion":[{"value":"28 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.\u00a0Th\u00f6lken, P.J.\u00a0Schuler, J.\u00a0Zenk und J.\u00a0Doescher geben an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F\u00fcr die dargestellten Originalstudien gelten die jeweils dort angegebenen ethischen Standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}